Search

MG98

MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.

CRA-028129

CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

ARX201

ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol … (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH).

Benzquinamide

Benzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. … The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.

GMI-1359

GMI-1359 is a small molecule, glycomimetic compound with dual inhibitory activity against E-selectin and CXCR4.[A261406]

ADL 10-0101

ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. … Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects.

XEN-2174

XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.

BTA9881

BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

Dibenzepin

Dibenzepin is approved for use in Europe.

TY027